Compare NEA & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEA | LIVN |
|---|---|---|
| Founded | N/A | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 2002 | 2015 |
| Metric | NEA | LIVN |
|---|---|---|
| Price | $11.34 | $58.84 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $72.43 |
| AVG Volume (30 Days) | ★ 828.6K | 639.0K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.79 |
| Revenue Next Year | N/A | $6.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.60 | $35.00 |
| 52 Week High | $11.90 | $71.58 |
| Indicator | NEA | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 42.12 | 33.20 |
| Support Level | $11.27 | $58.14 |
| Resistance Level | $11.46 | $65.61 |
| Average True Range (ATR) | 0.09 | 2.07 |
| MACD | -0.01 | -0.54 |
| Stochastic Oscillator | 13.04 | 2.85 |
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.